Additional support for a beneficial effect of class IIa HDACi in the management of HDAC4-expressing head and neck cancer cells comes from our gene expression study (RNAseq) in control and HDAC4-overexpressing Cal27 cells without and with 5 μM CHDI0039 treatment. Here, HDAC4 is linked to head and neck cancer.